All In Biotech

Drug Trial Radar · NCT00376883

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.

Last checked: Nov 20, 2026Latest source record: Jan 4, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Jan 2000

Primary completion

Not stated

Study completion Oct 2006

Sponsor

Lead sponsor
Nordic Myeloma Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nordic Cancer Union
First posted
Sep 15, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreased bone formation leading to bone pain and increased risk of fractures. The normal osteoclasts are responsible for bone degradation through stimulation from the malignant plasma cells. Bisphosphonates have been shown to inhibit the osteoclast activity but may have serious side-effects due to renal toxicity and the optimal dose have not been established. In a randomized double blinded design it is aim to compare the standard of monthly injections of 90 mg pamidronate with 30 mg. The primary end-point is physical function estimated by EORTC QLQ-C30 questionnaire at 12 months after starting the treatment in newly diagnosed treatment demanding multiple myeloma. Secondary end-points are skeletal related events, cost-utility analysis, response, response duration and survival and quality of life with respect to fatigue and pain.

Conditions

  • Multiple Myeloma

Interventions

  • pamidronateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Department of Haematology B, Aalborg Hospital, University of Aarhus

    Aalborg, Denmark

  • Hæmatologisk afd., Århus Universitetshospital

    Aarhus, Denmark

  • Department of Haematology, Herlev University Hospital

    Herlev, Denmark

  • Department of Hematology L, Rigshospitalet

    København Ø, Denmark

  • Hematologisk seksjon, med avd, Haukeland Universitetssykehus

    Bergen, Norway

  • Hematologisk avdeling Ullevål Sykehus

    Oslo, Norway

  • Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge

    Tromsø, Norway

  • Hematologisk seksjon, St.Olav Hospital

    Trondheim, Norway

  • Sahlgrenska Universitetsjukhuset Östra

    Gothenburg, Sweden

  • Hematologkliniken, Universitetssjukhuset

    Linköping, Sweden

  • Medicinklin, Universitetssjukhuset MAS,

    Malmö, Sweden

  • Medicinkliniken, Universitetssjukhuset

    Örebro, Sweden

  • Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus

    Umeå, Sweden

  • Medicinklinikken Akademiska sjukhuset

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.